Lower than expected second quarter results for AbbVie and Biogen, while Valeant (iNova) raised its full-year outlook. …
Latest Video
New Stories
-
'Patients can’t wait – swift action and access are the only possible moves from here'
August 26, 2025 - - Latest News -
Vaxxas secures $90 million in funding to commercialise needle-free vaccination delivery technology
August 25, 2025 - - Australian Biotech -
Bayer partners with Arrotex to strengthen access to oral contraceptives
August 25, 2025 - - Latest News -
The next negotiation was always going to be complicated, the new reality will make it more so
August 25, 2025 - - Latest News -
UK industry cites US pricing ambitions in collapse of new agreement negotiation
August 25, 2025 - - Latest News -
Botanix appoints Dr Patricia Walker as a non-executive director
August 25, 2025 - - Australian Biotech -
First site initiated for Neuren’s Phelan-McDermid syndrome Phase 3 trial
August 25, 2025 - - Australian Biotech